Autologous Cell Therapy After Stroke

Withdrawn before enrolling · Phase 1 · Has a placebo group

Conditions studied: Stroke

In brief

This study will examine the safety of two different cellular therapies in the treatment of stroke.

Key facts

Study ID

NCT00908856

Run by

University of California, Irvine

People needed

0

Starts

2016-01-01

Expected to finish

2017-12-01

Last updated by the study team

2016-02-04

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ischemic stroke that is supratentorial in location and < 72 hours old between stroke onset and bone marrow aspiration
• No major pre-stroke disability
• NIH stroke scale score of 7-24
• Able to undergo bedside bone marrow aspiration
• Age 18-85 years, inclusive
• Reasonable likelihood of receiving standard physical, occupational and speech rehabilitation therapy

You may not qualify if…

• No major active hematological, immunological, or oncological diagnoses
• Pregnancy
• Lactating mothers
• At least 24 hours time of any thrombolytic therapy and time of bone marrow aspiration
• Allergy to penicillin or to fetal bovine serum
• Active, major co-existent neurological or psychiatric disease
• Infection with HIV, hepatitis B or C, or syphilis
• Any diagnosis that makes survival to 90 days post-stroke unlikely
• Participation in an experimental therapeutic clinical trial in the prior three months

Where it is running

• UC Irvine Medical Center — Orange, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.